Plotkin et al. further highlighted that, while most adverse events were mild, a subset of patients experienced significant liver enzyme elevations, proteinuria, and hypertension, underscoring the cumulative risk associated with chronic bevacizumab therapy in NF2 patients who may require extended treatment durations [17]. Here, NF2 is linked to hypertensive disorder.